RenovoRx

Northwell Health Cancer Institute joins TIGeR-PaC study evaluating RenovoRx's TAMP therapy for locally advanced pancreatic cancer, aiming for full enrollment by mid-2025.

RenovoRx (RNXT) announced NHCI is enrolling patients with LAPC in its Phase III TIGeR-PaC trial, joining other U.S. clinical sites.

Northwell Health Cancer Institute joins RenovoRx's Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, evaluating TAMP therapy platform with intra-arterial gemcitabine via RenovoCath vs. standard IV chemotherapy, aiming to complete enrollment by H1 2025.

Northwell Health Cancer Institute joins TIGeR-PaC study evaluating RenovoRx's TAMP therapy for locally advanced pancreatic cancer, aiming for full enrollment by mid-2025.

The article discusses the importance of enabling JavaScript for optimal app performance.

The global oncolytic virus immunotherapy market, projected to exceed USD 1.50 billion by 2030, is advancing with over 180 therapies in clinical trials. Key therapies like IMLYGIC, Oncorine, and Delytact are approved, with more expected due to FDA and EMA designations. Innovations and partnerships, such as RenovoRx and Imugene's collaboration, are driving growth, aiming for safer, targeted cancer treatments.

RenovoRx announced four clinical data abstracts for RenovoGem™ and RenovoTAMP® accepted at the 2023 ASCO GI Symposium. RenovoGem, using RenovoTAMP for localized chemotherapy delivery, is in Phase III trials for LAPC and planned for eCCA studies in 2023. The TIGeR-PaC study aims to improve LAPC treatment efficacy and reduce side effects.